A FormBlends network publication
Compounding Explained

Who inspects a compounding pharmacy, and how to read what they found

State boards, FDA, and the documents each produces: inspection reports, Form 483 observations, warning letters, recalls, consent decrees. What each one means, where it is published, and how to search for a specific pharmacy.

By FormBlends editorial teamUpdated September 4, 2026Educational, not medical advice

"Inspected" is a word that appears on a lot of pharmacy websites. Inspected by whom, when, and what did they write down are the questions that matter. This page covers the two inspectors, the five documents they produce, and where to find each.

The two inspectors

State boards of pharmacy license 503A pharmacies and hold primary responsibility for their day-to-day oversight, in FDA's own phrase. Boards inspect on licensure and renewal and in response to complaints, apply the state's pharmacy act and the USP chapters it adopts, and can fine, restrict, suspend or revoke a licence. Their findings are published on the board's site, in formats that vary from a searchable database to scanned PDF orders. Every board is linked on the all 50 boards page.

FDA inspects 503B outsourcing facilities on a risk-based schedule and 503A pharmacies on surveillance or for cause. FDA applies the FD&C Act: CGMP for 503B, and for 503A the "insanitary conditions" prohibition and the conditions of section 503A itself. FDA publishes the results centrally.

The five documents

  1. Inspection report (Establishment Inspection Report) and state inspection report. The narrative of what was inspected. FDA EIRs are obtainable by FOIA; state reports vary.
  2. Form FDA 483. Handed to the firm at the close of an inspection when the investigator observed conditions that may violate the Act. It is a list of observations, numbered, in the investigator's words. It is not a finding of violation. FDA posts many compounding 483s on its compounding actions page.
  3. Warning letter. A formal letter stating that FDA has found significant violations, citing the statute, and asking for a written response, usually within 15 working days. Published in the warning letters database, searchable by company name, date and subject. The GLP-1 letters of 2023 to 2026 are all there; the enforcement timeline lists them with dates.
  4. Recall. Removal of a product from the market, almost always initiated by the firm, sometimes at FDA's request. Classified I, II or III by the health risk. Compounding recalls are on the compounding actions page and in FDA's enforcement reports.
  5. Consent decree, seizure or injunction. Court-enforced outcomes when the firm and FDA agree terms or FDA sues. Rare, public, and decisive.

How to search for a specific pharmacy

  • FDA compounding actions page. Alphabetical by company. Each entry lists 483s, warning letters, recalls and other actions with dates and links. Search the page for the pharmacy's legal name and any former names.
  • Registered outsourcing facilities page. If the compounder is a 503B facility, its row shows the initial and most recent registration dates, last inspection date, whether a 483 was issued, recall history and any action based on the last inspection. FDA notes that some columns are self-reported and unverified; the inspection columns are FDA's.
  • Warning letters database. Filter by subject "Compounding" or search the company name.
  • State board site. Licence lookup for status and expiry; disciplinary actions or board orders for history. Check the board of the state where the pharmacy is located, then your own state's board for the non-resident licence.

Reading what you find

A single 483 with corrected observations is ordinary. Repeat observations across inspections, a warning letter citing insanitary conditions or sterility failures, a Class I recall, or a state board order restricting sterile compounding are not. Dates matter: a 2019 warning letter followed by clean inspections tells a different story from a 2025 one with no response posted.

What you will not find is a rating. Neither FDA nor any state board scores pharmacies, and neither does this site. The vetting checklist gives you the search steps in order; what you make of the results is a conversation to have with your prescriber.

Questions people ask

A pharmacy has a Form 483. Should I avoid it?

A 483 lists what an inspector observed; the firm responds and FDA decides what, if anything, follows. Many inspections produce a 483 with observations that are corrected. Read the observations (FDA posts many of them), read the firm's response if available, and look at whether a warning letter, recall or consent decree followed. A pattern across years matters more than one document.

Where are state board disciplinary actions published?

On the board's own site, usually under licence lookup, disciplinary actions, or board orders, and typically by the board of the state where the pharmacy is physically located. The all-50-boards page links each one.

Does FDA inspect every 503A pharmacy?

No. State boards hold primary responsibility for day-to-day oversight of 503A pharmacies. FDA inspects some on a surveillance basis and others for cause, such as after adverse event reports or complaints, and publishes the outcomes on its compounding actions page.

Sources

  1. FDA: Compounding Inspections, Recalls, and Other Actions Accessed September 4, 2026.
  2. FDA: Registered Outsourcing Facilities (per-facility inspection, 483, recall and action columns) Accessed September 4, 2026.
  3. FDA: Warning Letters database Accessed September 4, 2026.
  4. FDA: Compounding and the FDA, Questions and Answers (state boards have primary day-to-day oversight of 503A; FDA inspects 503B on a risk-based schedule; content current as of September 16, 2025) Accessed September 4, 2026.

Canonical URL: https://formblendscompounding.com/explainers/who-inspects-a-compounding-pharmacy. Written by the FormBlends editorial team. This page is educational and is not medical advice; see the medical disclaimer.